Study type: In vitro · Status: Verified against declared source

Vasoactive Intestinal Chemical sequence (VIP) in COVID-19 Therapy-Shedding of ACE2 and TMPRSS2 via ADAM10.

International journal of molecular sciences · 2025

Study scale: Data are shown as the mean value of biological replicates, with error bars depicting the standard deviation.

Abstract only: Open source record

Product or molecular entity relationships

VIP: Exact entity relationship. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.

Plain-language verified summary

Question

In contrast to Temerezo et al., here, we show a reduction of in vitro cell infection by a SARS-CoV-2 pseudovirus upon VIP pretreatment.

Methods

Patients infected with SARS-CoV-2 may develop mild respiratory symptoms but also Acute Respiratory Distress Syndrome (ARDS).

Scale or participants

Data are shown as the mean value of biological replicates, with error bars depicting the standard deviation.

Key findings

Patients infected with SARS-CoV-2 may develop mild respiratory symptoms but also Acute Respiratory Distress Syndrome (ARDS).

Limitations and uncertainty

In the initial phase of the pandemic, several therapeutic options have been assessed either to inhibit viral replication or to overcome hyper-inflammation [5,6].

Verified against declared source. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.